Collaboration enables patients to access the Octave MSDA test at Quest's approximately 7,000 patient access sites across the U.S. and establishes a pathway to introduce additional tests from Octave's precision neurology portfolio over time.
Octave Bioscience, a commercial-stage precision care company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson's disease, today announced a strategic collaboration with Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, to make the OctaveⓇ Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest's nationwide specimen-collection network.
Providers that order the test from Octave will be able to refer patients with a test requisition to one of Quest's 7,000 patient service centers and in-office phlebotomists across the United States. It also gives Quest first rights to consider to provide specimen collection services for future novel tests Octave is developing for multiple sclerosis and Parkinson's disease.
"At Quest, we are committed to delivering diagnostics that empower people and their providers to make better-informed clinical decisions and advance the standard of care in neurodegenerative diseases like MS," said Michael Racke, MD, a board-certified neurologist and Senior Medical Director of Neurology, Quest Diagnostics. "The Octave MSDA Test is an important clinical innovation because it harnesses comparatively simple blood testing to illuminate relapse and treatment response in patients with MS, helping to reduce reliance on specialized imaging technologies alone. By making it available through our nationwide network of patient service centers, Quest is making it easier for patients and their physicians across the country to access these insights."